1. HOME
2. Research Insight
3. Biosense Webster (US), Abbott (US) and Boston Scientific Corporation (US) are the Major Players in the Cardiac Mapping Market

The global cardiac mapping market size is projected to reach USD 2.1 billion by 2024 from USD 1.4 billion in 2019, at a CAGR of 8.7%. The growing investments, funds, and grants, increasing incidence of target diseases, growth in the geriatric population, and new entrants in the market are important factors driving the growth of this market.

The major players in the cardiac mapping market include Biosense Webster (US), Abbott (US),  Medtronic (Ireland), Boston Scientific Corporation (US), MicroPort Scientific Corporation (China), EP Solutions SA (Switzerland), Acutus Medical (US), Koninklijke Philips N.V. (Royal Philips) (Netherlands), Lepu Medical  (China), BIOTRONIK (Germany), AngioDynamics (US), BioSig Technologies (US), APN Health (US), CoreMap (US), Kardium (Canada), Catheter Precision (US), and Epmap-System  (Germany). The analysis of market developments between 2017 and 2019 showed that market players adopted strategies such as product launches, & approvals, partnerships, agreements, & collaborations, acquisitions, and other developments to strengthen their product portfolios and maintain a competitive position in the cardiac mapping systems market.

To know about the assumptions considered for the study download the pdf brochure

Biosense Webster (US) held the dominant position in the cardiac mapping market in 2018. The large share of this company can be attributed to its strong suite of cardiac mapping systems, software, and catheters. The company provides products mainly targeted at the diagnosis and treatment of several cardiac arrhythmias, such as atrial fibrillation. Moreover, the firm has a strong geographic presence in all regions of the world. The company focuses on product launches to create a strong foothold in the market. In 2019, Biosense introduced the CARTONET, a cloud-based networking and data analytics software solution.

Abbott (US) held the second-largest share of the cardiac mapping market in 2018. The company offers an advanced EnSite Precision cardiac mapping system, along with sensor-enabled catheters compatible with the mapping system. The firm’s Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases. The firm focuses on organic & inorganic growth strategies. For instance, in 2018, the company received the US FDA approval for its Advisor HD Grid Mapping Catheter, Sensor Enabled, which can help optimize the accuracy of the cardiac image when paired with the EnSite Precision cardiac mapping system. Moreover, the company acquired St. Jude Medical (US), in 2017, thus expanding its product portfolio in cardiac rhythm management and electrophysiology market.

Boston Scientific Corporation (US) held the third-largest share of the cardiac mapping market in 2018. The company provides a cardiac mapping system along with ablation-mapping catheters. The company’s Rhythmia Mapping System is indicated for catheter-based atrial and ventricular mapping, which allows real-time visualization of intracardiac catheters as well as the display of cardiac maps in a number of different formats. Moreover, Boston Scientific has a strong geographic presence in more than 40 countries globally. In March 2016, the company collaborated with Mayo Clinic, US, to share intellectual property ideas for the development of new medical devices to address unmet clinical needs.

Related Reports:

Cardiac Mapping Market by Product (Contact Mapping Systems (Electroanatomical Mapping, Basket Catheter Mapping), Non-contact Mapping Systems), Indication (Atrial Fibrillation, Atrial Flutter, AVNRT), Region - Global Forecast to 2024

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]